Genomcore, a company dedicated to providing bioinformatics solutions through genomic medicine, wants to expand its market after recording a 73% increase in turnover in 2020.
The group has made its way thanks to its prices, which range from $73 (€60) to $359 (€295), making it possible to consolidate its position in the Iberian market. In the meantime, it has already set targets for expansion abroad, with the United Kingdom in its sights, according to Oscar Flores, CEO of Genomcore.
In 2020, the company had a turnover of $912,000 (€750,000), of which $244,000 (€200,000) came from research and development (R&D) projects. Looking ahead to 2021, the company aims to close the year with $1.34 million (€1.1 million) in turnover, which is equivalent to a forecast increase of 53 points. Of this figure, it is estimated that only $182,000 (€150,000) will come from R&D projects. In the last year, Genomcore has grown from 20 to 30 employees, which translates into a 50% increase in staff.
Born2Invest mobile application is bringing the latest biotech breakthroughs and the most important business news from trusted sources to a single screen so you can stay on top of the market. The application is aggregating the most important and breaking news from relevant websites, the list is always revised and updated with new resources.
Genomcore brings extra genetic information to recurrent analytical tests in hospitals, clinics, and primary care centers
The company has a range of genetic counseling through bioinformatics support. In this area, Genomcore provides extra genetic information to recurrent analytical tests in hospitals, clinics, and primary care centers. This process aims to facilitate “the diagnosis and treatment of different diseases,” according to Flores.
The company, founded in 2016, had an initial investment of $304,000 (€250,000). Since then, the company has doubled its sales annually. A fact that repeated in 2020, dodging the impact of the Covid-19 crisis. The coming year looks set to be a vital one for Genomcore. The company plans to expand its presence in other countries. In this particular case, the main target is the United Kingdom and the choice of this country is not random.
The expansion into the United Kingdom is seen as a preliminary step towards market expansion in the United States
In this process, the company has received investment from the innovation hub Wayra and also from the investment vehicle for start-ups CG Health Ventures. This expansion into the United Kingdom is seen as a preliminary step for market expansion in the United States. According to Flores, the U.S. market “is the one with the greatest economic potential for a company like Genomcore, which is oriented towards the healthcare sector.”
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [++ A2 Hosting Affiliates Review]
Something's brewing in the Right to Repair space. Lawmakers are increasingly law-making. DIY fixer upperers are increasingly fixer uppering. And,...
Why the Carbon Credit Market Is Not Working
The Carbon Brief analysis focused on 34 companies that alone used 38 million tons of carbon dioxide over the period...
Recrowd, Real Estate Lending Platform, Finally Gets European Authorization
Recrowd adopts a distinct approach for less sophisticated investors, limiting their investments to under €1,000 or 5% of their net...
Why the Amounts Invested in Belgian Fintech Companies Decreased
In 2023, the Belgian fintech sector has not witnessed any major fundraising events similar to those in previous years, such...
Bitcoin Soars 130% This Year: Will It Reach New All-Time Highs in 2024?
Bitcoin is currently trading within an ascending channel, maintaining support at $35,000, with an upward trajectory towards the psychological resistance...
Fintech1 week ago
Colombia Leads the Region’s Fintech Ecosystem Segment in Financial Inclusion
Crowdfunding3 days ago
f2o Sports Announced that Its Crowdfunding Campaign Has Started
Cannabis2 weeks ago
Why Snoop Dogg Is Quitting Smoking Cannabis
Crowdfunding1 week ago
E-Pop-Cycle Folding Bike at a Better Price via Crowdfunding